Core Insights - The company has a unique and broad product offering, which positions it well in the market [1] - There is a strong focus on innovation, which is central to the company's strategy and aims to assist customers effectively [2] Company Positioning - The CEO has been with the company for approximately 2.5 years and has served as CEO for 1.5 years, expressing excitement about the company's current positioning [1] - The company has successfully enhanced its commercial strategy, leading to closer relationships with major companies [1] Innovation Strategy - Innovation remains a core aspect of the company's identity, with ongoing efforts to double down on this focus [2] - The aim is to ensure that the company's innovations effectively support customer needs [2]

Repligen Conference Call Summary Company Overview - **Company**: Repligen (NasdaqGS:RGEN) - **Industry**: Bioprocessing and Life Sciences Key Points Company Positioning and Strategy - Repligen has a unique and broad product offering, with a strong focus on innovation, which is central to its strategy [2][3] - The company has successfully engaged with large pharmaceutical companies and contract development and manufacturing organizations (CDMOs) to showcase its extensive product portfolio [10] Product Differentiation - Approximately 80% of Repligen's portfolio is differentiated, focusing on unmet customer needs [4] - Key products include: - **ATF (Alternating Tangential Flow)**: Developed to enhance process intensification, allowing more output from the same footprint [4] - **Pre-packed Columns**: Addressing the challenge of finding skilled labor for column packing, providing a competitive advantage [5] - The remaining 20% of the portfolio focuses on customer-centric services, improving lead times and customer service [6] Customer Engagement and Market Growth - Visibility with major pharmaceutical accounts has significantly improved over the past 2.5 years, with a 2.5x increase in product lines sold to large accounts [10] - Repligen is now involved in 80-90% of major RFPs for bioprocessing equipment, indicating strong market presence [12] - The company is packaging technologies into full workflow solutions for specific customer needs, enhancing its value proposition [11] Financial Performance and Guidance - Repligen's guidance for 2026 is similar to the previous year's guidance, reflecting confidence in continued growth despite market headwinds [19][52] - The company aims for a 30% EBITDA margin and 25% EBIT margin by 2030, with a focus on price capture, volume leverage, and manufacturing productivity [27][28] - In 2025, Repligen achieved a 240 basis point expansion in EBIT margin, with a target of 150 basis points for 2026 [29] Market Dynamics and Competitive Landscape - The bioprocessing market is characterized by a significant portion of sales coming from consumables (75-80%), with equipment sales being more prominent during the initial setup of new facilities [16] - Repligen collaborates with competitors like Sartorius on certain technologies while maintaining a distinct market position [17][18] Innovation and Product Development - The company is focused on developing custom resins and ligands, significantly reducing development time compared to competitors [41][42] - Repligen is enhancing its process analytics portfolio through mergers and technology integration, aiming to lead in AI-enabled bioprocessing solutions [45][49] Future Outlook - Repligen anticipates a growth acceleration starting in 2027, driven by increased CapEx spending and improved FDA approval rates for biologics [55][56] - The company is optimistic about the future of bioprocessing, expecting several years of growth as market conditions improve [60] Additional Insights - The importance of talent acquisition in the bioprocessing industry is emphasized, with Repligen successfully attracting experienced professionals [36][37] - The company is actively monitoring regulatory changes and market dynamics that could impact growth and investment strategies [56][60]

Question-and-Answer SessionPuneet SoudaLeerink Partners LLC, Research Division Yes. Okay. Excellent. So maybe always exciting to talk about Repligen, a number of things you have ongoing for you in the markets, strong clinical stage presence that you have and in commercial as well. So maybe -- but let me kick off on the 2026 guide. You framed it as 9% to 13% organic growth rate. And then you pointed out the 500 bps outperformance framework relative to the bioprocessing end market, offset by 200 bps of headwi ...

Repligen (NasdaqGS:RGEN) 2026 Conference March 10, 2026 11:20 AM ET Company ParticipantsJacob Johnson - VP of Investor RelationsJason Garland - CFOModeratorGreat. Welcome everyone. I'm Puneet Souda. I cover life science tools and diagnostics here at Leerink, and it's my pleasure to be hosting the Repligen team, CFO Jason Garland, and also Head of Investor Relations, Jacob Johnson joining us. Great to have you guys here in Miami. Good morning.Jason GarlandThanks for having us, Puneet.ModeratorYeah. Okay, exc ...

Core Viewpoint - Repligen Corporation is actively participating in three upcoming investor conferences, highlighting its commitment to engaging with investors and stakeholders in the bioprocessing technology sector [1][4]. Company Overview - Repligen Corporation is a global life sciences company that specializes in developing and commercializing innovative bioprocessing technologies and systems aimed at enhancing the efficiency of biological drug manufacturing [3]. - The company serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, focusing on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3]. - Repligen's corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3]. Upcoming Conferences - Repligen will participate in the Leerink Global Healthcare Conference from March 8 to 11, 2026, with CFO Jason Garland scheduled for an analyst-led discussion on March 10 at 11:20 a.m. ET [4]. - The company will also attend the Barclays 28th Annual Global Healthcare Conference from March 10 to 12, 2026, where Jason Garland will speak on March 11 at 10:30 a.m. ET [4]. - Additionally, Repligen will be part of the 2026 KeyBanc Virtual Healthcare Forum on March 17 and 18, 2026, featuring CEO Olivier Loeillot in an analyst-led discussion on March 18 at 2:15 p.m. ET [4].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 41 Seyon Street, Bldg. 1, Suite 100 ...

Core Insights - Repligen Corporation (RGEN) reported fourth-quarter 2025 adjusted earnings per share of 49 cents, exceeding both the Zacks Consensus Estimate and the previous year's adjusted earnings of 44 cents per share [1] - Total revenues for the fourth quarter reached $198 million, reflecting an 18% year-over-year increase, and surpassing the Zacks Consensus Estimate of $192 million [1][6] - The company achieved 14% organic revenue growth in the fourth quarter, excluding acquisition and COVID-related revenues [5][6] Revenue Breakdown - Product revenues amounted to $197.7 million, up 18.1% from the previous year, while royalty and other revenues were $0.2 million, increasing by 20% year over year [4] - Revenues from consumables grew over 20%, and biopharma revenues increased by 20% year-over-year, driven by growth in both pharma and emerging biotech sectors [6] - Proteins and Process Analytics revenues grew more than 30%, while Chromatography revenues increased by over 25% year-over-year [7] Financial Performance - Adjusted gross margin was reported at 52.4%, an increase of 170 basis points year-over-year [8] - Adjusted operating income for the quarter was $30 million, reflecting a 20% increase from the previous year [8] - As of December 31, 2025, the company had cash and cash equivalents of $768 million, up from $749 million as of September 30, 2025 [9] Full-Year Results and Guidance - For the full year 2025, Repligen generated revenues of $738.3 million, representing approximately 16% growth year-over-year, with adjusted earnings of $1.71 per share, up from $1.58 per share in the prior year [10] - The company expects total revenues for 2026 to be in the range of $810-$840 million, with adjusted EPS anticipated between $1.93 and $2.01 [11] - Adjusted gross margin for 2026 is projected to be between 53.6% and 54.1%, with adjusted operating income expected to range from $122 million to $130 million [11]

Core Insights - Achieved 16% organic non-COVID revenue growth in 2025, significantly outpacing the broader bioprocessing market through portfolio diversity and commercial execution [1] Performance Highlights - Performance was driven by exceptional strength in Proteins and Analytics, which both grew over 30% in Q4, offsetting muted demand for downstream capital equipment [1] - Successfully expanded adjusted operating margins by 240 basis points on an organic basis by leveraging volume and pricing to offset inflationary pressures [1] Customer Engagement - Key account penetration strategy successfully increased product line adoption, with top customers now purchasing 2.5x more product lines compared to 2019 levels [1] Regional Growth - The Asia Pacific region grew 19% for the full year, supported by a strategic focus on China which returned to growth for two consecutive quarters [1] Strategic Initiatives - Strategic investments in 'Fit for Growth' initiatives, including IT modernization and AI in supply chain, were prioritized to build a scalable foundation for future volume [1]

Garland reported fourth-quarter adjusted gross profit of $104 million and adjusted gross margin of 52.4%, an increase of 170 basis points year-over-year. He attributed the improvement primarily to volume leverage and price, which more than offset inflation, with “slight headwinds from mix and tariffs.” For the full year, adjusted gross margin was 52.6%, up about 220 basis points from 2024 on similar drivers.CFO Jason Garland said acquisitions contributed about one percentage point to fourth-quarter reported ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...